Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis
The optimal antibiotic regimen is unclear in management of pulmonary infections due to pseudomonas and staphylococcus in cystic fibrosis (CF). We systematically searched all the published literature that has considered the evidence for antimicrobial therapies in CF till June 2013. The key findings w...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2013/645653 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561837188579328 |
|---|---|
| author | Rashmi Ranjan Das Sushil Kumar Kabra Meenu Singh |
| author_facet | Rashmi Ranjan Das Sushil Kumar Kabra Meenu Singh |
| author_sort | Rashmi Ranjan Das |
| collection | DOAJ |
| description | The optimal antibiotic regimen is unclear in management of pulmonary infections due to pseudomonas and staphylococcus in cystic fibrosis (CF). We systematically searched all the published literature that has considered the evidence for antimicrobial therapies in CF till June 2013. The key findings were as follows: inhaled antipseudomonal antibiotic improves lung function, and probably the safest/most effective therapy; antistaphylococcal antibiotic prophylaxis increases the risk of acquiring P. aeruginosa; azithromycin significantly improves respiratory function after 6 months of treatment; a 28-day treatment with aztreonam or tobramycin significantly improves respiratory symptoms and pulmonary function; aztreonam lysine might be superior to tobramycin inhaled solution in chronic P. aeruginosa infection; oral ciprofloxacin does not produce additional benefit in those with chronic persistent pseudomonas infection but may have a role in early or first infection. As it is difficult to establish a firm recommendation based on the available evidence, the following factors must be considered for the choice of treatment for each patient: antibiotic related (e.g., safety and efficacy and ease of administration/delivery) and patient related (e.g., age, clinical status, prior use of antibiotics, coinfection by other organisms, and associated comorbidities ones). |
| format | Article |
| id | doaj-art-52d01e3b0d3f4837bebc867089a84194 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-52d01e3b0d3f4837bebc867089a841942025-02-03T01:24:03ZengWileyThe Scientific World Journal1537-744X2013-01-01201310.1155/2013/645653645653Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic FibrosisRashmi Ranjan Das0Sushil Kumar Kabra1Meenu Singh2Department of Pediatrics, All India Institute of Medical Sciences, Bhubaneswar 751019, IndiaDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, IndiaDepartment of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, IndiaThe optimal antibiotic regimen is unclear in management of pulmonary infections due to pseudomonas and staphylococcus in cystic fibrosis (CF). We systematically searched all the published literature that has considered the evidence for antimicrobial therapies in CF till June 2013. The key findings were as follows: inhaled antipseudomonal antibiotic improves lung function, and probably the safest/most effective therapy; antistaphylococcal antibiotic prophylaxis increases the risk of acquiring P. aeruginosa; azithromycin significantly improves respiratory function after 6 months of treatment; a 28-day treatment with aztreonam or tobramycin significantly improves respiratory symptoms and pulmonary function; aztreonam lysine might be superior to tobramycin inhaled solution in chronic P. aeruginosa infection; oral ciprofloxacin does not produce additional benefit in those with chronic persistent pseudomonas infection but may have a role in early or first infection. As it is difficult to establish a firm recommendation based on the available evidence, the following factors must be considered for the choice of treatment for each patient: antibiotic related (e.g., safety and efficacy and ease of administration/delivery) and patient related (e.g., age, clinical status, prior use of antibiotics, coinfection by other organisms, and associated comorbidities ones).http://dx.doi.org/10.1155/2013/645653 |
| spellingShingle | Rashmi Ranjan Das Sushil Kumar Kabra Meenu Singh Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis The Scientific World Journal |
| title | Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis |
| title_full | Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis |
| title_fullStr | Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis |
| title_full_unstemmed | Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis |
| title_short | Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis |
| title_sort | treatment of pseudomonas and staphylococcus bronchopulmonary infection in patients with cystic fibrosis |
| url | http://dx.doi.org/10.1155/2013/645653 |
| work_keys_str_mv | AT rashmiranjandas treatmentofpseudomonasandstaphylococcusbronchopulmonaryinfectioninpatientswithcysticfibrosis AT sushilkumarkabra treatmentofpseudomonasandstaphylococcusbronchopulmonaryinfectioninpatientswithcysticfibrosis AT meenusingh treatmentofpseudomonasandstaphylococcusbronchopulmonaryinfectioninpatientswithcysticfibrosis |